1 To characterize bezlotoxumab PK in 2 age cohorts Age Cohort 1: 12 to 18 years Age Cohort 2: 1 to 12 years of pediatric participants to support dose selection in this population 2To evaluate the safety and tolerability of a single infusion of bezlotoxumab as compared with a single infusion of placebo through 12 weeks following infusion
Data and Resources
- A Randomized Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of a Single Infusion of Bezlotoxumab MK 6072 Human Monoclonal Antibody to C difficile Toxin B in Children Aged 1 to 18...json
1 To characterize bezlotoxumab PK in 2 age cohorts Age Cohort 1: 12 to 18...
|Release Date|| |
|Public Access Level|| |